دورية أكاديمية
أعرض في EDS

Safety and Efficacy of Laser Interstitial Thermal Therapy as Upfront Therapy in Primary Glioblastoma and IDH-Mutant Astrocytoma: A Meta-Analysis.

التفاصيل البيبلوغرافية
العنوان: Safety and Efficacy of Laser Interstitial Thermal Therapy as Upfront Therapy in Primary Glioblastoma and IDH-Mutant Astrocytoma: A Meta-Analysis.
المؤلفون: Pandey A; Department of Neurosurgery, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA., Chandla A; Department of Neurosurgery, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA., Mekonnen M; Department of Neurosurgery, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA., Hovis GEA; Department of Neurosurgery, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA., Teton ZE; Department of Neurosurgery, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA.; Harbor-UCLA Medical Center, Torrance, CA 90502, USA., Patel KS; Department of Neurosurgery, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA.; Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA., Everson RG; Department of Neurosurgery, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA.; Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA.; Department of Radiation Oncology, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA.; The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA 90502, USA.; Ronald Reagan UCLA Medical Center, Los Angeles, CA 90095, USA., Wadehra M; Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA.; Department of Pathology and Laboratory Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA., Yang I; Department of Neurosurgery, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA.; Harbor-UCLA Medical Center, Torrance, CA 90502, USA.; Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA.; Department of Radiation Oncology, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA.; The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA 90502, USA.; Ronald Reagan UCLA Medical Center, Los Angeles, CA 90095, USA.; Department of Head and Neck Surgery, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA.
المصدر: Cancers [Cancers (Basel)] 2024 Jun 03; Vol. 16 (11). Date of Electronic Publication: 2024 Jun 03.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Although primary studies have reported the safety and efficacy of LITT as a primary treatment in glioma, they are limited by sample sizes and institutional variation in stereotactic parameters such as temperature and laser power. The current literature has yet to provide pooled statistics on outcomes solely for primary brain tumors according to the 2021 WHO Classification of Tumors of the Central Nervous System (WHO CNS5). In the present study, we identify recent articles on primary CNS neoplasms treated with LITT without prior intervention, focusing on relationships with molecular profile, PFS, and OS. This meta-analysis includes the extraction of data from primary sources across four databases using the Covidence systematic review manager. The pooled data suggest LITT may be a safe primary management option with tumor ablation rates of 94.8% and 84.6% in IDH-wildtype glioblastoma multiforme (GBM) and IDH-mutant astrocytoma, respectively. For IDH-wildtype GBM, the pooled PFS and OS were 5.0 and 9.0 months, respectively. Similar to rates reported in the prior literature, the neurologic and non-neurologic complication rates for IDH-wildtype GBM were 10.3% and 4.8%, respectively. The neurologic and non-neurologic complication rates were somewhat higher in the IDH-mutant astrocytoma cohort at 33% and 8.3%, likely due to a smaller cohort size.
References: Oper Neurosurg (Hagerstown). 2020 Nov 16;19(6):641-650. (PMID: 32687571)
Neurosurg Focus. 2016 Oct;41(4):E10. (PMID: 27690656)
J Clin Laser Med Surg. 1992 Feb;10(1):37-40. (PMID: 10149909)
Neurosurgery. 2023 Aug 1;93(2):427-435. (PMID: 36861990)
J Clin Med. 2021 Jan 19;10(2):. (PMID: 33477796)
Oper Neurosurg (Hagerstown). 2023 Nov 1;25(5):435-440. (PMID: 37846139)
Neurosurgery. 2021 Aug 16;89(3):496-503. (PMID: 34156076)
J Clin Oncol. 2015 Dec 10;33(35):4145-50. (PMID: 26392096)
World Neurosurg. 2011 Dec;76(6):572-9. (PMID: 22251506)
Cancers (Basel). 2022 Jan 17;14(2):. (PMID: 35053618)
Neuro Oncol. 2021 Aug 2;23(8):1215-1217. (PMID: 34185090)
AJNR Am J Neuroradiol. 2015 Nov;36(11):1998-2006. (PMID: 26113069)
Acta Neurol Scand. 2003 Sep;108(3):201-8. (PMID: 12911464)
Neurooncol Adv. 2019 Dec 16;2(1):vdz035. (PMID: 32793888)
Neurooncol Adv. 2020 Jun 30;2(1):vdaa071. (PMID: 32666049)
Neuro Oncol. 2022 Oct 3;24(10):1613-1646. (PMID: 35762249)
PeerJ. 2020 Jan 27;8:e8398. (PMID: 32025372)
Radiology. 2022 Sep;304(3):494-508. (PMID: 35880978)
J Neurosurg. 2015 Feb;122(2):280-96. (PMID: 25397366)
Pediatr Neurosurg. 2023;58(3):150-159. (PMID: 37232001)
World Neurosurg. 2020 Dec;144:e156-e163. (PMID: 32795682)
BMJ. 2021 Mar 29;372:n71. (PMID: 33782057)
Stat Methods Med Res. 2023 Feb;32(2):373-388. (PMID: 36412105)
Neurosurgery. 2013 Dec;73(6):1007-17. (PMID: 24056317)
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):721-6. (PMID: 14967426)
Med Sci Monit. 2018 Dec 21;24:9292-9299. (PMID: 30573725)
Int Wound J. 2024 Jan;21(1):e14628. (PMID: 38272817)
J Neurooncol. 2023 Sep;164(2):405-412. (PMID: 37505379)
World Neurosurg. 2014 Mar-Apr;81(3-4):652.e1-4. (PMID: 24140996)
N Engl J Med. 2005 Mar 10;352(10):997-1003. (PMID: 15758010)
J Neurosurg. 2013 Jun;118(6):1202-19. (PMID: 23560574)
Neurosurgery. 2018 Sep 1;83(3):556-565. (PMID: 29438526)
Neurosurg Focus. 2016 Oct;41(4):E14. (PMID: 27690658)
PLoS One. 2016 Feb 24;11(2):e0148613. (PMID: 26910903)
Asian J Neurosurg. 2020 Dec 21;15(4):800-808. (PMID: 33708647)
Front Oncol. 2018 Oct 31;8:499. (PMID: 30430083)
Neurosurgery. 2019 Dec 1;85(6):762-772. (PMID: 30476325)
Tomography. 2023 Aug 22;9(5):1551-1567. (PMID: 37736977)
Vascul Pharmacol. 2002 Jun;38(6):339-48. (PMID: 12529928)
World Neurosurg. 2018 Sep;117:e588-e594. (PMID: 29933086)
Lasers Med Sci. 2022 Apr;37(3):1811-1820. (PMID: 34687390)
J Neurooncol. 2021 Feb;151(3):429-442. (PMID: 33611709)
J Neurooncol. 2019 Apr;142(2):309-317. (PMID: 30656529)
Neurosurgery. 2016 Dec;79 Suppl 1:S17-S23. (PMID: 27861322)
Neurosurgery. 2020 Sep 1;87(3):E338-E346. (PMID: 32315434)
Acta Neurochir (Wien). 2022 Sep;164(9):2453-2464. (PMID: 35879477)
World Neurosurg. 2018 Sep;117:e146-e153. (PMID: 29883824)
Acta Neurochir (Wien). 2020 Dec;162(12):3005-3018. (PMID: 32617678)
Oper Neurosurg (Hagerstown). 2023 Apr 1;24(4):383-390. (PMID: 36701559)
Cancer Med. 2014 Aug;3(4):971-9. (PMID: 24810945)
Neuro Oncol. 2014 Jan;16(1):113-22. (PMID: 24285550)
Adv Drug Deliv Rev. 2022 Jun;185:114311. (PMID: 35489652)
Acta Neurochir (Wien). 2019 Jan;161(1):99-107. (PMID: 30465276)
Curr Oncol. 2022 Apr 08;29(4):2550-2563. (PMID: 35448183)
Cancer Imaging. 2019 Oct 15;19(1):65. (PMID: 31615562)
Neuroradiology. 2022 Oct;64(10):1919-1950. (PMID: 35869291)
Cancer. 2022 Jan 1;128(1):47-58. (PMID: 34633681)
Neurooncol Pract. 2023 Feb 03;10(3):281-290. (PMID: 37188164)
Neurosurgery. 2022 Dec 1;91(6):e160-e163. (PMID: 36377926)
J Neurosurg. 2017 Apr;126(4):1238-1245. (PMID: 27257839)
J Comput Assist Tomogr. 1994 Jul-Aug;18(4):519-32. (PMID: 8040431)
NeuroRx. 2005 Jan;2(1):3-14. (PMID: 15717053)
J Immunother. 2023 Nov-Dec 01;46(9):351-354. (PMID: 37727953)
J Neurosurg. 2013 Apr;118(4):801-8. (PMID: 23373806)
Mo Med. 2020 Jan-Feb;117(1):50-55. (PMID: 32158050)
Nat Rev Neurol. 2022 Sep;18(9):515-529. (PMID: 35729337)
Neurosurgery. 2020 Aug 1;87(2):266-275. (PMID: 31742351)
N Engl J Med. 2008 Jul 31;359(5):492-507. (PMID: 18669428)
Int J Mol Sci. 2020 Apr 16;21(8):. (PMID: 32316096)
Neurosurgery. 2016 Dec;79 Suppl 1:S8-S16. (PMID: 27861321)
Medicine (Baltimore). 2019 Nov;98(45):e17759. (PMID: 31702627)
J Cereb Blood Flow Metab. 2017 May;37(5):1670-1686. (PMID: 27356551)
Sci Rep. 2023 Feb 25;13(1):3279. (PMID: 36841878)
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. (PMID: 34185076)
Radiol Imaging Cancer. 2023 Nov;5(6):e230078. (PMID: 37861422)
Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-12. (PMID: 32324425)
Cureus. 2020 Dec 20;12(12):e12186. (PMID: 33489596)
Neuroscience. 2009 Jul 7;161(3):926-39. (PMID: 19362131)
J Neurosurg Case Lessons. 2022 Jul 4;4(1):CASE21373. (PMID: 35855352)
Neurooncol Adv. 2022 Apr 29;4(1):vdac042. (PMID: 35505674)
Stat Methods Med Res. 2021 Dec;30(12):2701-2719. (PMID: 34668458)
AJNR Am J Neuroradiol. 2022 Jul;43(7):928-937. (PMID: 35710121)
Neurosurgery. 2019 Apr 1;84(4):836-843. (PMID: 30137606)
J Neurosurg Case Lessons. 2022 Dec 5;4(23):. (PMID: 36471578)
Lasers Surg Med. 2018 Sep;50(9):917-923. (PMID: 29799137)
Cost Eff Resour Alloc. 2016 Mar 21;14:6. (PMID: 27006643)
Lasers Surg Med. 2003;33(2):75-80. (PMID: 12913878)
Neurosurg Focus. 2016 Oct;41(4):E12. (PMID: 27690657)
Neurooncol Adv. 2022 Apr 06;4(1):vdac040. (PMID: 35611270)
Oncol Lett. 2020 Jun;19(6):3761-3774. (PMID: 32391094)
Neuro Oncol. 2010 Feb;12(2):116-21. (PMID: 20150378)
Br J Neurosurg. 2024 Jun;38(3):632-638. (PMID: 34240676)
World J Surg. 1983 Nov;7(6):700-9. (PMID: 6419477)
فهرسة مساهمة: Keywords: 5-ALA; LITT; glioblastoma; immunotherapy; malignant gliomas; meningioma; molecular targeted therapy; primary brain tumors; skull-based tumors; vaccine therapy
تواريخ الأحداث: Date Created: 20240619 Latest Revision: 20240620
رمز التحديث: 20240620
مُعرف محوري في PubMed: PMC11171930
DOI: 10.3390/cancers16112131
PMID: 38893250
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers16112131